A Phase 4 interventional study of Ranibizumab in Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 47th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2014, is one of 33 in phase 4, and was the 90th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 33rd largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2014, is one of 18 in phase 4, and was the 38th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye responsible for vision). Patients can suffer with severe visual loss and have difficulties with every day tasks such as recognising faces, reading \& driving.
There are two variations of the disease, a 'dry' type \& a 'wet' type also known as neovascular AMD (nAMD). In wet/nAMD new vessels grow from the blood supply underneath the retina, in part due to higher than normal levels of a protein called Vascular Endothelial Growth Factor (VEGF). Since the introduction of drugs which block VEGF, visual outcomes for patients with wAMD have dramatically improved.
There are 2 widely used treatments; ranibizumab and aflibercept. Whilst the majority of patients have a successful outcome with treatment, many patients experience suboptimal response. This study evaluated if these patients experience a benefit from a switch to a different antiVEGF drug treatment.
In this study nAMD patients who are showing no or poor to response to treatment with aflibercept were switched to ranibizumab to assess if there is any benefit in terms of treatment outcomes.
Patients visited the hospital clinic 8 times over the 7 - 8 month study period. Monthly ranibizumab injections were given for the first 3 months, then monthly as required for the next 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 2. Suboptimal treatment response
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
Drug: Ranibizumab
Intraveal injections of 0.5mg ranibizumab
Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 90.
Measurement of the change in CSRT, determined by high definition optical coherence tomography (HD-OCT) after 3 monthly injections of ranibizumab. OCT is a non-invasive technique which can determine and measure thickness of the retina. A negative change from Baseline indicates an improvement (less retinal fluid and lower disease activity). Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 90
Change in Subfoveal Retinal Thickness (SRT) From Baseline to Day 180
Measurement of change in SRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 180
Measurement of change in CSRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Change in Central Subfield Retinal Volume (CSRV) From Baseline to Day 180
Measurement of change in CSRV from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Number of Patients With Intraretinal Fluid Assessed at Baseline and Day 180
Presence or absence of qualitative OCT parameter Intraretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Number of Patients With Subretinal Fluid Assessed at Baseline and Day 180
Presence or absence of qualitative OCT parameter Subretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline to Day 180
Number of Patients With Intraretinal/Subretinal Fluid Within the Central Subfield Fluid Assessed at Baseline and Day 180
Presence or absence of qualitative OCT parameter Intraretinal/Subretinal Fluid Within the Central Subfield. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Number of Patients With Pigment Epithelial Detachments Assessed at Baseline and Day 180
Presence or absence of qualitative OCT parameter Pigment Epithelial Detachments. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Number of Patients With Dry Retina Assessed at Baseline and Day 180
Presence or absence of qualitative OCT parameter Dry Retina. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Change in Maximum PED Height From Baseline to Day 180
Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Height. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Change in Maximum PED Diameter From Baseline to Day 180
Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Diameter. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Change in Maximum IRC Height From Baseline to Day 180
Change from Baseline to Day 180 in Maximum Intraretinal Cyst (IRC) Height. Data collected on the study eye were used for the evaluation of efficacy.
Time frame: Baseline and Day 180
Change in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA was assessed as letters read and measured in a sitting position using subjective refraction and Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.
Time frame: Baseline, Day 90 and Day 180
Change in ETDRS Letters for Study Eye From Baseline to Day 180
Number of patients gaining at least 15 letters from Baseline to Day 180
Time frame: Baseline and Day 180
Incidence of Ocular TEAEs in the Study Eye Reported by ≥2% Patients From Baseline to Day 180
Incidence of ocular Treatment Emergent Adverse Events (TEAEs) in the study eye reported by ≥2% patients by preferred term.
Time frame: Baseline to Day 180
Patients were recruited from 22 sites located in the United Kingdom and 6 sites located in Germany. A total of 103 patients received at least 1 dose of study drug.
| Milestone | Ranibizumab |
|---|---|
| Started | 103 |
| Full analysis set (fas) population | 100 |
| Safety (saf) population | 100 |
| Completed | 92 |
| Not completed | 11 |
| Withdrew: Protocol violation | 8 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Adverse event | 2 |
Measurement of the change in CSRT, determined by high definition optical coherence tomography (HD-OCT) after 3 monthly injections of ranibizumab. OCT is a non-invasive technique which can determine and measure thickness of the retina. A negative change from Baseline indicates an improvement (less retinal fluid and lower disease activity). Data collected on the study eye were used for the evaluation of efficacy.
| micrometer | Ranibizumab |
|---|---|
| Baseline | 384.00 (154.0 to 975.0) |
| Day 90 | 318.00 (170.0 to 832.0) |
| Change from Baseline to Day 90 | -30.75 (-386.0 to 78.0) |
Measurement of change in SRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.
| micrometer | Ranibizumab |
|---|---|
| SRT at Baseline | 346.00 (69.0 to 944.5) |
| SRT at Day 180 | 302.00 (41.5 to 876.5) |
| SRT change from Baseline to Day 180 | -23.50 (-464.0 to 306.5) |
Measurement of change in CSRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.
| micrometer | Ranibizumab |
|---|---|
| CSRT at Baseline | 384.00 (154.0 to 975.0) |
| CSRT at Day 180 | 343.00 (194.0 to 842.0) |
| CSRT change from Baseline to Day 180 | -28.00 (-271.0 to 171.0) |
Measurement of change in CSRV from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.
| cubic micrometer | Ranibizumab |
|---|---|
| CSRV at Baseline | 0.3050 (0.120 to 11.600) |
| CSRV at Day 180 | 0.2750 (0.115 to 11.400) |
| CSRV change from Baseline to Day 180 | -0.0200 (-1.600 to 0.135) |
Presence or absence of qualitative OCT parameter Intraretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.
| Participants | Ranibizumab |
|---|---|
| Baseline — Yes, Definitive | 32 |
| Baseline — Yes, Subtle | 11 |
| Baseline — No | 56 |
| Baseline — Questionable | 1 |
| Day 180 — Yes, Definitive | 24 |
| Day 180 — Yes, Subtle | 15 |
| Day 180 — No | 55 |
| Day 180 — Questionable | 0 |
Presence or absence of qualitative OCT parameter Subretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.
| Participants | Ranibizumab |
|---|---|
| Baseline — Yes, Definitive | 83 |
| Baseline — Yes, Subtle | 5 |
| Baseline — No | 12 |
| Day 180 — Yes, Definitive | 49 |
| Day 180 — Yes, Subtle | 15 |
| Day 180 — No | 30 |
Presence or absence of qualitative OCT parameter Intraretinal/Subretinal Fluid Within the Central Subfield. Data collected on the study eye were used for the evaluation of efficacy.
| Participants | Ranibizumab |
|---|---|
| Baseline — Yes, Definitive | 38 |
| Baseline — Yes, Subtle | 6 |
| Baseline — No | 5 |
| Baseline — Questionable | 1 |
| Baseline — NA | 50 |
| Day 180 — Yes, Definitive | 26 |
| Day 180 — Yes, Subtle | 12 |
| Day 180 — No | 15 |
| Day 180 — Questionable | 1 |
| Day 180 — NA | 40 |
Presence or absence of qualitative OCT parameter Pigment Epithelial Detachments. Data collected on the study eye were used for the evaluation of efficacy.
| Participants | Ranibizumab |
|---|---|
| Baseline — Yes, Definitive | 86 |
| Baseline — Yes, Subtle | 2 |
| Baseline — No | 12 |
| Baseline — Not gradable | 0 |
| Day 180 — Yes, Definitive | 80 |
| Day 180 — Yes, Subtle | 4 |
| Day 180 — No | 8 |
| Day 180 — Not gradable | 2 |
Presence or absence of qualitative OCT parameter Dry Retina. Data collected on the study eye were used for the evaluation of efficacy.
| Participants | Ranibizumab |
|---|---|
| Baseline — Yes, Definitive | 0 |
| Baseline — No | 100 |
| Day 180 — Yes, Definitive | 0 |
| Day 180 — No | 94 |
Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Height. Data collected on the study eye were used for the evaluation of efficacy.
| micrometer | Ranibizumab |
|---|---|
| Baseline | 236.00 (66.5 to 674.0) |
| Day 180 | 203.50 (63.5 to 705.0) |
| Change from Baseline to Day 180 | -2.50 (-336.5 to 131.0) |
Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Diameter. Data collected on the study eye were used for the evaluation of efficacy.
| micrometer | Ranibizumab |
|---|---|
| Baseline | 2205.00 (0.0 to 4877.0) |
| Day 180 | 2428.00 (471.0 to 4683.0) |
| Change from Baseline to Day 180 | 59.50 (-1007.0 to 2756.0) |
Change from Baseline to Day 180 in Maximum Intraretinal Cyst (IRC) Height. Data collected on the study eye were used for the evaluation of efficacy.
| micrometer | Ranibizumab |
|---|---|
| Baseline | 121.50 (21.0 to 280.5) |
| Day 180 | 105.50 (25.5 to 485.0) |
| Change from Baseline to Day 180 | 0.00 (-223.5 to 235.0) |
BCVA was assessed as letters read and measured in a sitting position using subjective refraction and Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.
| letters | Ranibizumab |
|---|---|
| Baseline | 71.5 (36 to 90) |
| Day 90 | 74.0 (32 to 87) |
| Day 180 | 75.0 (32 to 90) |
| Change from Baseline to Day 180 | 1.0 (-31 to 35) |
| Change from Day 90 to Day 180 | 0.0 (-25 to 24) |
Number of patients gaining at least 15 letters from Baseline to Day 180
| Participants | Ranibizumab |
|---|---|
| >=15 (Gain of at least 15 letters) | 11 |
| 10 to <15 | 6 |
| 5 to <10 | 17 |
| 0 to <5 | 25 |
| >-15 to <0 | 31 |
| <=-15 (Loss of at least 15 letters) | 7 |
| NA | 3 |
Incidence of ocular Treatment Emergent Adverse Events (TEAEs) in the study eye reported by ≥2% patients by preferred term.
| Participants | Ranibizumab |
|---|---|
| Eye pain | 3 |
| Visual impairment | 3 |
| Blepharitis | 2 |
| Posterior capsule opacification | 2 |
| Intraocular pressure increased | 3 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 6 months.. Non-serious events are listed at a 1.9% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab | 0/100 (0%) | 10/100 (10%) | 52/100 (52%) |
| Event | Ranibizumab |
|---|---|
| FALLInjury, poisoning and procedural complications | 3/100 |
| ANAEMIABlood and lymphatic system disorders | 1/100 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/100 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/100 |
| ATRIAL FLUTTERCardiac disorders | 1/100 |
| RETINAL HAEMORRHAGEEye disorders | 1/100 |
| DIARRHOEAGastrointestinal disorders | 1/100 |
| UPPER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/100 |
| VOMITINGGastrointestinal disorders | 1/100 |
| NON-CARDIAC CHEST PAINGeneral disorders | 1/100 |
| Event | Ranibizumab |
|---|---|
| NASOPHARYNGITISInfections and infestations | 9/100 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 7/100 |
| COUGHRespiratory, thoracic and mediastinal disorders | 7/100 |
| BLEPHARITISEye disorders | 6/100 |
| BLOOD PRESSURE INCREASEDInvestigations | 4/100 |
| DRY EYEEye disorders | 3/100 |
| EYE PAINEye disorders | 3/100 |
| VISUAL IMPAIRMENTEye disorders | 3/100 |
| INTRAOCULAR PRESSURE INCREASEDInvestigations | 3/100 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/100 |
FAS
| Age, Continuous(years) | Ranibizumab |
|---|---|
| Mean | 77 ± 6.51 |
| Sex: Female, Male(Participants) | Ranibizumab |
|---|---|
| Female | 55 |
| Male | 45 |
| Race/Ethnicity, Customized(Participants) | Ranibizumab |
|---|---|
| Caucasian | 99 |
| Asian | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2014 to primary completion in Sep 2017, 36 months.
Results were first posted in Feb 2019, 1 year 5 months after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 36 months is above that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab